A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel GRoup, MulticEnter Study in PatientS with Diabetic Peripheral Neuropathic Pain (PROGRESS)
Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (PROGRESS)
Sponsor: Lexicon Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAV0543
U.S. Govt. ID: NCT06203002
Contact: Jorge Cabrera, CRC: / jec2273@cumc.columbia.edu
Additional Study Information: To be in this study you must have Diabetic Peripheral Neuropathic (DPN) and be 18 years of age, inclusive, with the presence of bilateral pain in lower extremities due to DPN for at least 6 months prior to Screening and be in a stable regimen for the treatment of T1DM or T2DM for 3 months prior to Screening.
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Diabetic Peripheral Neuropathic Pain (DPNP)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jorge Cabrera, CRC
jec2273@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE